Target Name: NAT1
NCBI ID: G9
Other Name(s): Arylamine N-acetyltransferase 1 (isoform a) | Arylamine N-acetyltransferase, monomorphic | N-acetyltransferase 1, transcript variant 9 | ARY1_HUMAN | NAT1 variant 5 | N-acetyltransferase type 1 | NATI | NAT1 variant 1 | N-acetyltransferase 1, transcript variant 5 | Arylamide acetylase 1 | N-acetyltransferase 1 (arylamine N-acetyltransferase) | arylamide acetylase 1 | Arylamine N-acetyltransferase 1 | Arylamide acetylase 1 (N-acetyltransferase 1) | NAT-1 | N-acetyltransferase 1 | N-acetyltransferase 1, transcript variant 1 | NAT1 variant 9 | Monomorphic arylamine N-acetyltransferase | AAC1 | monomorphic arylamine N-acetyltransferase | MNAT

NAT1: Potential Drug Target Or Biomarker for Arylamine Detoxification

NAT1 (Arylamine N-acetyltransferase 1 (isoform a)) is a gene that encodes a protein involved in the detoxification of arylamines, which are compounds that can be toxic to humans and animals. Arylamines are formed when certain substances, such as some drugs, are metabolized by the liver. When arylamines are metabolized, they can be converted into potentially harmful compounds, such as arylamine N-oxide, which has been linked to certain cancers.

The NAT1 gene has been identified as a potential drug target or biomarker because it is involved in the detoxification of arylamines. This means that if a drug is able to inhibit the activity of NAT1, it may be able to reduce the formation of arylamines in the body, which could potentially reduce the risk of certain cancers.

One way that NAT1 has been studied is through cell-based assays. These assays involve growing cells in culture and exposing them to different compounds, such as drugs, in order to determine how the cells respond to those compounds. By analyzing the activity of NAT1 in these cell-based assays, researchers have been able to determine that NAT1 is involved in the detoxification of arylamines.

Another way that NAT1 has been studied is through animal models. In these models, researchers have been able to confirm that NAT1 is involved in the detoxification of arylamines. For example, researchers have found that when animals are given a drug that is known to induce arylamines, the levels of NAT1 activity in the animals' liver decrease. This suggests that NAT1 plays a role in the detoxification of arylamines in animals.

While more research is needed to fully understand the role of NAT1 in the detoxification of arylamines, it is clear that it is a potential drug target or biomarker. The development of drugs that can inhibit the activity of NAT1 could potentially lead to new treatments for certain cancers.

Protein Name: N-acetyltransferase 1

Functions: Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens

More Common Targets

NAT10 | NAT14 | NAT16 | NAT2 | NAT8 | NAT8B | NAT8L | NAT9 | NATD1 | Natural cytotoxicity triggering Receptor | NAV1 | NAV2 | NAV2-AS5 | NAV2-AS6 | NAV3 | NAXD | NAXE | nBAF complex | NBAS | NBAT1 | NBDY | NBEA | NBEAL1 | NBEAL2 | NBEAP1 | NBEAP3 | NBL1 | NBN | NBPF1 | NBPF10 | NBPF11 | NBPF12 | NBPF14 | NBPF15 | NBPF17P | NBPF18P | NBPF19 | NBPF20 | NBPF22P | NBPF25P | NBPF26 | NBPF3 | NBPF4 | NBPF5P | NBPF6 | NBPF7P | NBPF8 | NBPF9 | NBR1 | NBR2 | NCALD | NCAM1 | NCAM1-AS1 | NCAM2 | NCAN | NCAPD2 | NCAPD3 | NCAPG | NCAPG2 | NCAPH | NCAPH2 | NCBP1 | NCBP2 | NCBP2-AS1 | NCBP2AS2 | NCBP3 | NCCRP1 | NCDN | NCEH1 | NCF1 | NCF1B | NCF1C | NCF2 | NCF4 | NCF4-AS1 | NCK1 | NCK1-DT | NCK2 | NCKAP1 | NCKAP1L | NCKAP5 | NCKAP5-AS2 | NCKAP5L | NCKIPSD | NCL | NCLN | NCMAP | NCMAP-DT | NCOA1 | NCOA2 | NCOA3 | NCOA4 | NCOA5 | NCOA6 | NCOA7 | NCOR1 | NCOR1P1 | NCOR2 | NCR1 | NCR2